Patents by Inventor Victor Kotelianski

Victor Kotelianski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR MODULATION OF GENES ASSOCIATED WITH MUSCLE HEALTH
    Publication number: 20230203180
    Abstract: Aspects of the disclosure relate to molecular payloads that modulate the expression or activity of genes involved in muscle growth and maintenance (e.g., MSTN, INHBA, ACVR1B, MLCK1, ACVR1, FBXO32, TRIM63, MEF2D, KLF15, MED1, MED13, and/or PPP1R3A), and complexes comprising a muscle-targeting agent covalently linked to such molecular payloads. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on a muscle cell (e.g., a cardiac muscle cell, a smooth muscle cell, a skeletal muscle cell). In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
    Type: Application
    Filed: July 8, 2022
    Publication date: June 29, 2023
    Applicant: Dyne Therapeutics, Inc.
    Inventors: Romesh R. Subramanian, Mohammed T. Qatanani, Cody A. Desjardins, Duncan Brown, Victor Kotelianski, Timothy Weeden, Brendan Quinn, John Najim
  • MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR MODULATION OF GENES ASSOCIATED WITH MUSCLE HEALTH
    Publication number: 20230111147
    Abstract: Aspects of the disclosure relate to molecular payloads that modulate the expression or activity of genes involved in muscle growth and maintenance (e.g., MSTN, INHBA, and/or ACVR1B), and complexes comprising a muscle-targeting agent covalently linked to such molecular payloads. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on a muscle cell (e.g., a cardiac muscle cell). In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
    Type: Application
    Filed: January 8, 2021
    Publication date: April 13, 2023
    Applicant: Dyne Therapeutics, Inc.
    Inventors: Romesh R. Subramanian, Mohammed T. Qatanani, Cody A. Desjardins, Duncan Brown, Victor Kotelianski, Timothy Weeden, Brendan Quinn
  • COMPOSITIONS AND METHODS DIRECTED TO TREATING LIVER FIBROSIS
    Publication number: 20210087218
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the COL1A1, TGF-?, and SMAD2/3 genes, and methods of using such dsRNA compositions to inhibit expression of COL1A1, TGF-?, and SMAD2/3.
    Type: Application
    Filed: May 6, 2020
    Publication date: March 25, 2021
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Gregory Hinkle, Victor Kotelianski, Brian Bettencourt, Alfica Sehgal, Tatiana Novobrantseva
  • Compositions and methods directed to treating liver fibrosis
    Patent number: 10669303
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the COL1A1, TGF-?, and SMAD2/3 genes, and methods of using such dsRNA compositions to inhibit expression of COL1A1, TGF-?, and SMAD2/3.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: June 2, 2020
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Gregory Hinkle, Victor Kotelianski, Brian Bettencourt, Alfica Sehgal, Tatiana Novobrantseva
  • Compositions and methods for increasing erythropoietin (EPO) production
    Patent number: 10233452
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting one or more EGLN genes, EGLN1, EGLN2 and/or EGLN3 and methods of using such dsRNA compositions to inhibit expression of these genes.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: March 19, 2019
    Assignees: Dana-Farber Cancer Institute, Inc., Alnylam Pharmaceuticals, Inc.
    Inventors: William G. Kaelin, Jr., Victor Kotelianski, William Querbes, Brian Bettencourt
  • COMPOSITIONS AND METHODS DIRECTED TO TREATING LIVER FIBROSIS
    Publication number: 20190016751
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the COL1A1, TGF-?, and SMAD2/3 genes, and methods of using such dsRNA compositions to inhibit expression of COL1A1, TGF-?, and SMAD2/3.
    Type: Application
    Filed: February 26, 2018
    Publication date: January 17, 2019
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Greg Hinkle, Victor Kotelianski, Brian Bettencourt, Alfica Sehgal, Tatiana Novobrantseva
  • Compositions and methods directed to treating liver fibrosis
    Patent number: 9944671
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the COL1A1, TGF-?, and SMAD2/3 genes, and methods of using such dsRNA compositions to inhibit expression of COL1A1, TGF-?, and SMAD2/3.
    Type: Grant
    Filed: June 2, 2011
    Date of Patent: April 17, 2018
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Greg Hinkle, Victor Kotelianski, Brian Bettencourt, Alfica Sehgal, Tatiana Novobrantseva
  • COMPOSITIONS AND METHODS FOR INCREASING ERYTHROPOIETIN (EPO) PRODUCTION
    Publication number: 20160177313
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting one or more EGLN genes, EGLN1, EGLN2 and/or EGLN3 and methods of using such dsRNA compositions to inhibit expression of these genes.
    Type: Application
    Filed: October 19, 2015
    Publication date: June 23, 2016
    Inventors: William G. Kaelin, JR., Victor Kotelianski, William Querbes, Brian Bettencourt
  • Compositions and methods for inhibiting expression of the PCSK9 gene
    Patent number: 9260718
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: February 16, 2016
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor Kotelianski
  • Compositions and methods for increasing erythropoietin (EPO) production
    Patent number: 9193973
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting one or more EGLN genes, EGLN1, EGLN2 and/or EGLN3 and methods of using such dsRNA compositions to inhibit expression of these genes.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: November 24, 2015
    Assignees: Alynylam Pharmaceuticals, Inc., Dana-Farber Cancer Institute
    Inventors: William G. Kaelin, Jr., Victor Kotelianski, William Querbes, Brian Bettencourt
  • Compositions and Methods for Inhibiting Expression of the PCSK9 Gene
    Publication number: 20140350075
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression.
    Type: Application
    Filed: July 14, 2014
    Publication date: November 27, 2014
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor Kotelianski
  • COMPOSITIONS AND METHODS FOR INCREASING ERYTHROPOIETIN (EPO) PRODUCTION
    Publication number: 20140024699
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting one or more EGLN genes, EGLN1, EGLN2 and/or EGLN3 and methods of using such dsRNA compositions to inhibit expression of these genes.
    Type: Application
    Filed: December 9, 2011
    Publication date: January 23, 2014
    Applicants: DANA-FARBER CANCER INSTITUTE, ALNYLAM PHARMACEUTICALS, INC.
    Inventors: William G. Kaelin, JR., Victor Kotelianski, William Querbes, Brian Bettencourt
  • COMPOSITIONS AND METHODS DIRECTED TO TREATING LIVER FIBROSIS
    Publication number: 20130158097
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the COL1A1, TGF-?, and SMAD2/3 genes, and methods of using such dsRNA compositions to inhibit expression of COL1A1, TGF-?, and SMAD2/3.
    Type: Application
    Filed: June 2, 2011
    Publication date: June 20, 2013
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Greg Hinkle, Victor Kotelianski, Brian Bettencourt, Alfica Sehgal, Tatiana Novobrantseva
  • METHOD FOR THE TREATMENT OF INFLAMMATORY DISORDERS
    Publication number: 20120087925
    Abstract: A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.
    Type: Application
    Filed: November 15, 2011
    Publication date: April 12, 2012
    Applicant: BIOGEN IDEC MA INC.
    Inventors: Philip Gotwals, Antonin de Fougerolles, Roy Lobb, Victor Kotelianski
  • Method for the treatment of inflammatory disorders
    Patent number: 8084031
    Abstract: A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.
    Type: Grant
    Filed: November 11, 2008
    Date of Patent: December 27, 2011
    Assignee: Biogen Idec MA Inc.
    Inventors: Philip Gotwals, Antonin De Fougerolles, Roy Lobb, Victor Kotelianski
  • Polynucleotides encoding members of the human B lymphocyte activation antigen B7 family and polypeptides encoded thereby
    Patent number: 7968680
    Abstract: The present invention provides novel isolated BLAA polynucleotides and the membrane-associated or secreted polypeptides encoded by the BLAA polynucleotides. Also provided are the antibodies that immunospecifically bind to a BLAA polypeptide or any derivative, variant, mutant or fragment of the BLAA polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the BLAA polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: June 28, 2011
    Assignee: Biogen Idec MA Inc.
    Inventors: Cynthia Green, Victor Kotelianski, Antonin De Fougerolles, John Carulli, Catherine Hession
  • METHOD FOR THE TREATMENT OF INFLAMMATORY DISORDERS
    Publication number: 20090324598
    Abstract: A method for the treatment of inflammatory disorders is disclosed, particularly the treatment of arthritis. The method comprises the administration of a function blocking antibody which is capable of binding an epitope of VLA-1.
    Type: Application
    Filed: November 11, 2008
    Publication date: December 31, 2009
    Applicant: Biogen Idec MA Inc.
    Inventors: Philip Gotwals, Antonin De Fougerolles, Roy Lobb, Victor Kotelianski
  • Polynucleotides Encoding Members of the Human B Lymphocyte Activation Antigen B7 Family and Polypeptides Encoded Thereby
    Publication number: 20090047217
    Abstract: The present invention provides novel isolated BLAA polynucleotides and the membrane-associated or secreted polypeptides encoded by the BLAA polynucleotides. Also provided are the antibodies that immunospecifically bind to a BLAA polypeptide or any derivative, variant, mutant or fragment of the BLAA polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the BLAA polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.
    Type: Application
    Filed: November 20, 2007
    Publication date: February 19, 2009
    Inventors: Cynthia Green, Victor Kotelianski, Antonin de Fougerolles, John Carulli, Catherine Hession
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE
    Publication number: 20080113930
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene.
    Type: Application
    Filed: May 10, 2007
    Publication date: May 15, 2008
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor Kotelianski
  • Humanized antibodies against monocyte chemotactric proteins
    Publication number: 20070134236
    Abstract: The invention provides humanized antibodies that bind to a plurality of b-chemokines, particularly monocyte chemotactic proteins MCP-1, MCP-2 and MCP-3. The invention also provides therapeutic reagents and methods of treating disorders associated with detrimental MCP activity.
    Type: Application
    Filed: November 25, 2003
    Publication date: June 14, 2007
    Inventors: Antonin De Fougerolles, Victor Kotelianski, Ellen Garber, Carl Reid, Jose Saldanha, Herman Vlijmen